Research Papers: Pathology:
Assessment and diagnostic relevance of novel serum biomarkers for early decision of ST-elevation myocardial infarction
Metrics: PDF 1686 views | HTML 1625 views | ?
Hun-Jun Park1,*, Ji Heon Noh2,3,*, Jung Woo Eun2,3,*, Yoon-Seok Koh1, Suk Min Seo1, Won Sang Park2, Jung Young Lee2, Kiyuk Chang1, Ki Bae Seung1, Pum-Joon Kim1, Suk Woo Nam2,3,4
1Department of Cardiology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
2Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3Functional RNomics Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
4Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
*These authors have contributed equally to this work
Suk Woo Nam, e-mail: firstname.lastname@example.org
Pum-Joon Kim, e-mail: email@example.com
Keywords: ST-segment-elevation myocardial infarction, peripheral blood transcriptome, molecular signature, diagnostic biomarkers
Received: March 25, 2015 Accepted: May 04, 2015 Published: May 18, 2015
Blood transcriptome reflects the status of diseases, and characteristic molecular signature provides a novel window on gene expression preceding acute coronary events. We aim to determine blood transcriptome-based molecular signature of acute coronary syndrome (ACS), and to identify novel serum biomarkers for early stage ST-segment-elevation myocardial infarction (STEMI). We obtained peripheral blood from the patients with ACS who visited emergency department within 4 hours after the onset of chest pain: STEMI (n = 10), Non-ST-segment-elevation MI (NSTEMI, n = 10) and unstable angina (UA, n = 11). Blood transcriptome scans revealed that a characteristic gene expression change exists in STEMI, resulting in 531 outlier genes as STEMI molecular signature (Welch’s t test, P < 0.05). Another analysis with a set of blood samples of patients with STEMI (n = 7) before and 7 days after the primary percutaneous coronary intervention (n = 7) and normal control (n = 10) evidenced that STEMI molecular signature directly reflects the onset of STEMI pathogenesis. From the two sets of transcriptome-based STEMI signatures, we identified 10 genes encoding transmembrane or secretory proteins that are highly expressed in STEMI. We validated blood protein expression levels of these 10 putative biomarkers in 40 STEMI and 32 healthy subjects by ELISA. Data suggested that PGLYRP1, IRAK3 and VNN3 are more specific and sensitive diagnostic biomarkers for STEMI than traditional CK-MB or troponin.
Blood transcriptome scans of ACS evidenced early stage molecular markers for STEMI. Here, we report novel biomarkers to diagnose STEMI at emergency department in hospitals by a simple ELISA method.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.